MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY

Smart overview of the Invention

The nanocarrier consists of a silica body with numerous pores designed to encapsulate molecules. It is coated with a lipid bilayer that contains a cargo-trapping agent, which interacts with specific cargos like drugs. This lipid bilayer effectively seals the pores, ensuring stable encapsulation of the cargo.

Government Support and Sequence Listing

The development received support from the National Institutes of Health under specific grant numbers, granting the government certain rights. Additionally, the application includes a Sequence Listing in XML format, adhering to WIPO standards, which is incorporated by reference.

Background on Pancreatic Cancer Treatment

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited survival rates. Current treatments like FOLFIRINOX show better efficacy than gemcitabine but come with significant toxicity, largely due to irinotecan. Efforts to mitigate this involve using nanocarriers for targeted delivery, reducing systemic exposure.

Challenges with Existing Nanocarrier Systems

Traditional carriers such as polymeric particles and liposomes have limitations like low drug loading capacity and premature release. Although liposomal formulations have advanced to clinical trials, issues like instability and high toxicity persist, necessitating improved delivery systems.

Innovative Solution with LB-MSNP Platform

The proposed mesoporous silica nanoparticle (MSNP) platform enhances irinotecan delivery by utilizing a lipid bilayer coating for stability and controlled release. This approach reduces toxicity while maintaining efficacy, offering a promising first-line treatment option for PDAC with improved safety margins.